Albuminuria and Estimated Glomerular Filtration Rate Independently Associate with Acute Kidney Injury

Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Journal of the American Society of Nephrology (Impact Factor: 9.34). 10/2010; 21(10):1757-64. DOI: 10.1681/ASN.2010010128
Source: PubMed


Acute kidney injury (AKI) is increasingly common and a significant contributor to excess death in hospitalized patients. CKD is an established risk factor for AKI; however, the independent graded association of urine albumin excretion with AKI is unknown. We analyzed a prospective cohort of 11,200 participants in the Atherosclerosis Risk in Communities (ARIC) study for the association between baseline urine albumin-to-creatinine ratio and estimated GFR (eGFR) with hospitalizations or death with AKI. The incidence of AKI events was 4.0 per 1000 person-years of follow-up. Using participants with urine albumin-to-creatinine ratios <10 mg/g as a reference, the relative hazards of AKI, adjusted for age, gender, race, cardiovascular risk factors, and categories of eGFR were 1.9 (95% CI, 1.4 to 2.6), 2.2 (95% CI, 1.6 to 3.0), and 4.8 (95% CI, 3.2 to 7.2) for urine albumin-to-creatinine ratio groups of 11 to 29 mg/g, 30 to 299 mg/g, and ≥300 mg/g, respectively. Similarly, the overall adjusted relative hazard of AKI increased with decreasing eGFR. Patterns persisted within subgroups of age, race, and gender. In summary, albuminuria and eGFR have strong, independent associations with incident AKI.

Full-text preview

Available from:
  • Source
    • "Chronic kidney disease (CKD) represents a large burden among affected patients and on the healthcare system in the U.S. Approximately 26 million U.S. individuals have impaired kidney function or albuminuria [1]; the majority of these patients also have other significant co-morbid conditions such as diabetes mellitus, hypertension and cardiovascular disease [2]. Patients with CKD have significantly higher risk for hospital admissions [3-5], acute kidney injury [6], and cardiovascular-related death [7]. Moreover, CKD-associated costs have increased significantly, with CKD comprising 5.8% in 2000 to now 16% in 2009 of total Medicare costs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative (KDOQI) developed guidelines to care for patients with chronic kidney disease (CKD). While these are disseminated through the NKF's website and publications, the guidelines' usage remains suboptimal. The KDOQI Educational Committee was formed to identify barriers to guideline implementation, determine provider and patient educational needs and develop tools to improve care of patients with CKD. An online survey was conducted from May to September 2010 to evaluate renal providers' familiarity, current use of and attitudes toward the guidelines and tools to implement the guidelines. Most responders reported using the guidelines often and felt that they could be easily implemented into clinical practice; however, approximately one-half identified at least one barrier. Physicians and physician extenders most commonly cited the lack of evidence supporting KDOQI guidelines while allied health professionals most commonly listed patient non-adherence, unrealistic guideline goals and provider time-constraints. Providers thought that the guidelines included too much detail and identified the lack of a quick resource as a barrier to clinical implementation. Most were unaware of the Clinical Action Plans. Perceived barriers differed between renal clinicians and allied health professionals; educational and implementation tools tailored for different providers are needed.
    Full-text · Article · Oct 2013 · BMC Nephrology
  • Source
    • "The Atherosclerosis Risk in Communities study enrolled 11,200 patients in order to evaluate the relationship between proteinuria and AKI. The results showed that the risk of AKI increased with the severity of albuminuria [30]. Although clinicians have exerted efforts to prevent cisplatin-induced AKI, the results are not satisfactory [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cisplatin-induced acute kidney injury (AKI) is a major concern among clinicians in prescribing cisplatin-based chemotherapy. This study evaluated and compared the ability of urinary biomarkers, including urinary neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, and the urinary albumin to creatinine ratio (ACR) to predict cisplatin-induced AKI. Thirty-three cancer patients receiving cisplatin-based chemotherapy were prospectively studied, including 10 (30%) who developed AKI (the study group). Changes of urinary biomarkers were compared at 4 hours, 8 hours, and 12 hours, and 1 day, 2 days, 3 days, and 4 days after cisplatin intravenous infusions (75mg/m(2)) versus the baseline. There was a significant increase in urinary NGAL levels from 12 hours to 4 days (p<0.05) compared to baseline after cisplatin infusion in the AKI group. The magnitude of these changes over time differed significantly by group (p<0.001). The area under the receiver operating curve describing the relationship between urinary NGAL levels and AKI within 12 hours was 0.865 (95% confidence interval=0.691-1.000). Urinary NGAL levels independently predicted AKI 12 hours after cisplatin (p=0.045) after adjustments for age, gender, body mass index, baseline serum creatinine, and urinary total protein. Urinary NGAL levels may be an early biomarker of AKI in patients receiving cisplatin-based treatment.
    Full-text · Article · Jun 2013 · The Kaohsiung journal of medical sciences
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: GaInAsN cells are measured to retain 93 ± 3% and 89 ± 4% of their original efficiency after exposure to 5 × 10<sup>14</sup> and 1 × 10<sup>15</sup> cm<sup>-2</sup> 1-MeV electrons, respectively. The rate of degradation is not correlated with the performance at beginning of life (BOL). The depletion width remains essentially unchanged, increasing by < 1%. Temperature-coefficient data for GaInAsN cells are also presented. These numbers are used to project the efficiency of GaInAsN-containing multijunction cells. The GaInAsN junction is not currently predicted to increase the efficiencies of the multijunction cells. Nevertheless, GaInAsN-containing multijunction cell efficiencies are predicted to be comparable to those of the conventional structures, and even small improvements in the GaInAsN cell may lead to higher multijunction cell efficiencies, especially for high-radiation applications and when cell operating temperature is low.
    Full-text · Conference Paper · Jun 2002
Show more